The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies

被引:1
|
作者
Ren, Jiaqi [1 ,2 ]
Lv, Linlin [1 ]
Tao, Xufeng [1 ]
Zhai, Xiaohan [1 ]
Chen, Xuyang [1 ]
Yu, Hao [1 ,2 ]
Zhao, Xinya [1 ,2 ]
Kong, Xin [1 ,2 ]
Yu, Zhan [1 ]
Dong, Deshi [1 ]
Liu, Jing [3 ]
机构
[1] Dalian Med Univ, Dept Pharm, Affiliated Hosp 1, Dalian, Peoples R China
[2] Dalian Med Univ, Sch Pharm, Dalian, Peoples R China
[3] Dalian Med Univ, Affiliated Hosp 1, Stem Cell Clin Res Ctr, Natl Joint Engn Lab, Dalian, Peoples R China
关键词
CBL; cancer; E3 ubiquitin ligase; targeted therapy; immunotherapy; GROWTH-FACTOR RECEPTOR; TRAIL-INDUCED APOPTOSIS; CELL LUNG-CANCER; SMALL-MOLECULE INHIBITOR; C-CBL; GASTRIC-CANCER; PROSTATE-CANCER; TYROSINE KINASE; DOWN-REGULATION; E3; LIGASE;
D O I
10.3389/fphar.2024.1432545
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CBL (Casitas B-lineage lymphoma) family, as a class of ubiquitin ligases, can regulate signal transduction and activate receptor tyrosine kinases through various tyrosine kinase-dependent pathways. There are three members of the family: c-CBL, CBL-b, and CBL-c. Numerous studies have demonstrated the important role of CBL in various cellular pathways, particularly those involved in the occurrence and progression of cancer, hematopoietic development, and regulation of T cell receptors. Therefore, the purpose of this review is to comprehensively summarize the function and regulatory role of CBL family proteins in different human tumors, as well as the progress of drug research targeting CBL family, so as to provide a broader clinical measurement strategy for the treatment of tumors.
引用
收藏
页数:24
相关论文
共 50 条
  • [41] Degradation of HER2 by cbl-based chimeric ubiquitin Ligases
    Li, Xia
    Shen, Liangliang
    Zhang, Jing
    Su, Jin
    Shen, Lan
    Liu, Xinping
    Han, Hua
    Han, Wei
    Yao, Libo
    CANCER RESEARCH, 2007, 67 (18) : 8716 - 8724
  • [42] Understanding the role of Cripto-1 in cancer progression and therapeutic strategies
    Qingfang Zeng
    Yuzhen Gao
    Ying Zhou
    Clinical and Translational Oncology, 2023, 25 : 1135 - 1144
  • [43] Understanding the role of Cripto-1 in cancer progression and therapeutic strategies
    Zeng, Qingfang
    Gao, Yuzhen
    Zhou, Ying
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (05): : 1135 - 1144
  • [44] Ubiquitin-protein ligases - Novel therapeutic targets?
    Robinson, PA
    Ardley, HC
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2004, 5 (03) : 163 - 176
  • [45] Role of the E3 Ubiquitin Ligase CBL Family in Cardiovascular Diseases
    Xu, Xingli
    Cui, Qinghua
    CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2024, 9 (01) : 1 - 4
  • [46] c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses
    Thien, CBF
    Langdon, WY
    BIOCHEMICAL JOURNAL, 2005, 391 : 153 - 166
  • [47] E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities
    Basu, Bhaskar
    Kal, Satadeepa
    Karmakar, Subhajit
    Basu, Malini
    Ghosh, Mrinal K.
    LIFE SCIENCES, 2024, 336
  • [48] T Cell Activation and the Role of Ubiquitin Ligases
    Lu, Xiaolong
    Singh, Rajesh
    Song, Changcheng
    Mason, Mark
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [49] The Nedd4-like family of E3 ubiquitin ligases and cancer
    Chen, Ceshi
    Matesic, Lydia E.
    CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) : 587 - 604
  • [50] Up-regulation of the Cbl family of ubiquitin ligases is involved in ATRA and bufalin-induced cell adhesion but not cell differentiation
    Qu, Xiujuan
    Liu, Yunpeng
    Ma, Yanju
    Zhang, Ye
    Li, Yingchun
    Hou, Kezou
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 367 (01) : 183 - 189